 |
Theodora Agalioti (Institute
of Molecular Biology and
Genetics) and John
Strouboulis (Institute of
Molecular Oncology)
participate in the FP7 Marie
Curie Initial Training
Network
DisChrom which aims to
study the molecular
mechanisms underlying
chromatin diseases, the
potential for therapeutic
intervention and the
development of new
technologies to dissect the
epigenetic abnormalities
associated with these
conditions. |
|
|
 |
Three Fleming groups (George Kollias, Dimitris Kontoyiannis and George Panayotou) participate in the FP7 Large scale integrating project
INFLACARE aiming at “Understanding inflammation-associated tumorigenesis for the rational design of novel anti-cancer therapeutic strategies”. The program runs from 2009-2012 and is funded by the EC. More information will follow soon.
|
|
|
 |
George Kollias and Dimitris Kontoyiannis from Fleming’s Institute of Immunology take part in FP7’s Large scale integrating project
MASTERSWITCH,
that runs for 5 years
(2009-2013) aiming to
discover “Mechanisms to
Attack Steering Effectors of
Rheumatoid Syndromes with
Innovative Therapy Choices”. |
|
|
 |
Fleming is a key partner of
INFRAFRONTIER, the European Ιnfrastructure for phenotyping and archiving of model mammalian genomes. INFRAFRONTIER is a Combination of Collaborative Project (CP) and Coordination and Support Actions (CSA) and will be funded by the EC from 2008-2011. |
|
|
 |
BSRC Al. Fleming researchers participate in
CREATE (Coordination of resources for conditional expression of mutated mouse alleles), a co-ordination Action of the 7th Framework Programme of the European Commission, aiming to disseminate extant information on Cre driver strains through generation of an international CreZOO database, develop a roadmap for harnessing emerging technologies and methods for improving Cre-mediated recombination in vivo through targeted, intensive workshops and finally to define the requirements of the mouse research community, by collecting information on new Cre expression patterns necessary for in-depth analysis of mutagenesis in different cell and tissue types through a CreExpress forum.
|
|
|
 |
Three research groups from the
Institutes of Molecular Oncology (Strouboulis) and
Molecular Biology and Genetics (Talianidis, Agalioti) participate in the
FP7 Marie Curie Initial Training Network
InteGeR aimed at an integrated approach to studying gene regulation in cellular differentiation, thus contributing to a better understanding of physiological and disease mechanisms.
More info. |
|
|
 |
BSRC Al. Fleming researchers take part in
I-DCC (The International Data Coordination Centre), a co-ordination Action of the 7th Framework Programme of the European Commission, aiming to lead an effort to establish common data formats and a single portal of access to information on all mutant ES cell resources. The project includes key scientists and bioinformaticians actively involved in the three ongoing large-scale mouse knock out projects (EUCOMM,
KOMP and
NorCOMM). |
|
 |
Al. Fleming researchers
participate in
CASIMIR, a co-ordination Action of the 6th Framework
Programme of the European Comission, aiming to gather
together information and make recommendations on the
integration of databases and resources throughout Europe
that contain genetic and phenotypic data of relevance to
the mouse as a model organism for human disease.
see related
press release | read about the
database revolution |
|
 |
MUGEN
network of Excellence (MUGEN NoE) is a consortium of
21 leading research institutes and universities, aiming
to structure and shape a world-class framework of
European scientific and technological excellence in the
field of murine models for immunological diseases and
immune processes and to advance the understanding of the
genetic basis of disease and enhance innovation and
raise public awareness of scientific research efforts. |
|
 |
Researchers of the Institute of Immunology, participate
in EURO-RA, a Marie Curie Research Training
Network that brings together leading groups in the field
of Arthritis research in Europe and aims to identify
susceptibility genes that determine the onset,
progression and chronicity of autoimmune arthritis the
most common chronic inflammatory autoimmune disease
affecting the European population |
|
|
 |
Researchers of BSRC Al.
Fleming contribute to a
EU consortium in
order to propose strategies
for balancing the
pathogenic/beneficial
effects of TNF in
opportunistic infections
appearing in anti-TNF
treated patients.
More info |
|
 |
BSRC Al. Fleming’s researchers participate in
EUMODIC, a primary phenotype assessment project of
up to 650 mouse mutant lines derived from ES cells
developed in the
EUCOMM
project. Lines showing an interesting phenotype will be
subject to a more in depth assessment. EUMODIC will
build upon the comprehensive database of standardised
phenotyping protocols, called
EMPReSS, developed by the
EUMORPHIA project. EUMODIC has developed a selection
of these screens, called EMPReSSslim, to enable
comprehensive, high throughput, primary, phenotyping of
large numbers of mice. |
|
 |
Fleming researchers take part in the European research
project
RIGHT
– RNA Interference Technology as Human Therapeutic Tool
– which involves 24 research institutes and enterprises
throughout Europe. The goal of the project is to promote
the application of RNA interference technology for human
therapy by combining expertises of leading European
scientists in a multidisciplinary approach. |
